Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaime Masjuan

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Stroke|April 27, 2026
Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind StudyMartin Köhrmann, Jörg Berrouschot, Joaquín Serena, et al.
Frontiers in Immunology|August 25, 2025
Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosisAlexander Rodero-Romero, José Ignacio Fernández-Velasco, Enric Monreal, et al.
Frontiers in Immunology|July 29, 2021
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple SclerosisCarmen Picón, Amalia Tejeda-Velarde, José Ignacio Fernández-Velasco, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 7, 2021
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MSJosé I Fernández-Velasco, Jens Kuhle, Enric Monreal, et al.
Lancet (London, England)|September 5, 2022
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trialAshkan Shoamanesh, Hardi Mundl, Eric E Smith, et al.
International Journal of Molecular Sciences|July 29, 2025
Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple SclerosisEnric Monreal, José Ignacio Fernández-Velasco, Susana Sainz de la Maza, et al.
JAMA Neurology|February 27, 2023
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy DrugsEnric Monreal, José Ignacio Fernández-Velasco, María Isabel García-Sánchez, et al.
Frontiers in Immunology|April 7, 2022
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis PathologyJosé I Fernández-Velasco, Enric Monreal, Jens Kuhle, et al.
International Journal of Molecular Sciences|September 9, 2023
Genetic Architecture of Ischaemic Strokes after COVID-19 Shows Similarities with Large Vessel StrokesLaia Llucià-Carol, Elena Muiño, Natalia Cullell, et al.
Therapeutic Advances in Neurological Disorders|May 15, 2026
Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective studyJuan Luis Chico-Garcia, Moisés Morales de la Prida, Almudena Boix Lago, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Stroke|April 27, 2026
Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind StudyMartin Köhrmann, Jörg Berrouschot, Joaquín Serena, et al.
Frontiers in Immunology|August 25, 2025
Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosisAlexander Rodero-Romero, José Ignacio Fernández-Velasco, Enric Monreal, et al.
Frontiers in Immunology|July 29, 2021
Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple SclerosisCarmen Picón, Amalia Tejeda-Velarde, José Ignacio Fernández-Velasco, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 7, 2021
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MSJosé I Fernández-Velasco, Jens Kuhle, Enric Monreal, et al.
Lancet (London, England)|September 5, 2022
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trialAshkan Shoamanesh, Hardi Mundl, Eric E Smith, et al.
International Journal of Molecular Sciences|July 29, 2025
Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple SclerosisEnric Monreal, José Ignacio Fernández-Velasco, Susana Sainz de la Maza, et al.
JAMA Neurology|February 27, 2023
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy DrugsEnric Monreal, José Ignacio Fernández-Velasco, María Isabel García-Sánchez, et al.
Frontiers in Immunology|April 7, 2022
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis PathologyJosé I Fernández-Velasco, Enric Monreal, Jens Kuhle, et al.
International Journal of Molecular Sciences|September 9, 2023
Genetic Architecture of Ischaemic Strokes after COVID-19 Shows Similarities with Large Vessel StrokesLaia Llucià-Carol, Elena Muiño, Natalia Cullell, et al.
Therapeutic Advances in Neurological Disorders|May 15, 2026
Rituximab and IVIG added to plasma exchange improves the outcome of severe CNS demyelinating attacks: a retrospective studyJuan Luis Chico-Garcia, Moisés Morales de la Prida, Almudena Boix Lago, et al.
Pageof 11